PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50120C00177MCMS develop medical countermeasures THAT — Vedanta Biosciences, Inc

Vedanta Biosciences, Inc holds $63.0M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Aug 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Vedanta Biosciences, Inc

Recipient

Aug 31, 2027

PoP end

$91.8M

Obligated

541714

NAICS

AZ13

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Vedanta Biosciences, Inc — $90

Contract facts

NONE

Contract number75A50120C00177

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentVedanta Biosciences, Inc

UEIC91JJXT9QND5

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAZ13

Place of performanceBOSTON, MA

Related solicitationBAA-18-100-SOL-00003

PoP end (current)Aug 31, 2027

PoP end (w/ options)Dec 31, 2031

Obligated$91.8M

TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Vedanta Biosciences, Inc. Estimated value $99.1M ($91.8M obligated). Current period of performance ends Aug 31, 2027 (potential Dec 31, 2031). Last award drew 1 bidder. Place of performance: BOSTON, MA. Related solicitation BAA-18-100-SOL-00003.

TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.

Recompete timing

Public

● Expiring in 358 days

Current PoP ends Aug 31, 2027 (358 days remaining). Agencies typically plan 12–18 months ahead — at 11.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Vedanta Biosciences, Inc — $63.0M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$63.0M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50120C00177?

75A50120C00177 (MCMS develop medical countermeasures THAT) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $99.1M, currently held by Vedanta Biosciences, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50120C00177?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50120C00177 to Vedanta Biosciences, Inc.

Who is the incumbent on 75A50120C00177?

Vedanta Biosciences, Inc is the incumbent with $63.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.

When does Vedanta Biosciences, Inc’s 75A50120C00177 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50120C00177 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jul 21, 2026